Home 禄 Business 禄 Manufacturing
Pfizer's vaccine sale
By Cathy Ding |
June 1, 2010, Tuesday
|
Print Edition
Print Edition
PFIZER Inc is said to have sold its swine vaccine business in China to Harbin Pharmaceutical Group.
Harbin Pharmaceutical has paid US$50 million for these assets, Reuters said, citing an unnamed source close to the deal.
A communications official from Pfizer yesterday said the company "did sell some of the animal health operations in China recently," but didn't give further details.
Pfizer will sell its China operations to manufacture its RespiSure and RespiSure-One swine mycoplasma hyopneumoniae (MH) vaccines to Harbin Bio-Vaccine, an animal health unit of Harbin Pharmaceutical.
The divestment is said to be connected to Pfizer's US$68 billion merger with Wyeth, as China's Ministry of Commerce ordered Pfizer to sell its local business citing anti-monopoly regulations, Reuters said.
Harbin Pharmaceutical has paid US$50 million for these assets, Reuters said, citing an unnamed source close to the deal.
A communications official from Pfizer yesterday said the company "did sell some of the animal health operations in China recently," but didn't give further details.
Pfizer will sell its China operations to manufacture its RespiSure and RespiSure-One swine mycoplasma hyopneumoniae (MH) vaccines to Harbin Bio-Vaccine, an animal health unit of Harbin Pharmaceutical.
The divestment is said to be connected to Pfizer's US$68 billion merger with Wyeth, as China's Ministry of Commerce ordered Pfizer to sell its local business citing anti-monopoly regulations, Reuters said.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
